These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from competitors and generate strong returns for shareholders
But if investing a company with a strong moat is a great idea, wouldn't it be even better to buy one that has no direct competition at all? Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR), and Acadia Pharmaceuticals (NASDAQ: ACAD).
Image source: Getty Images.
Source: Fool.com
Acadia Pharmaceuticals Aktie
17,22 €
-0,64 %
Starkes Kaufinteresse bei Acadia Pharmaceuticals, mit einer großen Anzahl an Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 31 € für Acadia Pharmaceuticals bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 17.22 €.
